A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 28 Mar 2018
At a glance
- Drugs INCAGN 1949 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 30 Nov 2016 According to an Agenus Inc. media release, the first patient has been dosed in this trial.
- 08 Nov 2016 Status changed from not yet recruiting to recruiting.
- 03 Oct 2016 Status changed from planning to not yet recruiting.